Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...
Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...
Revenue growth was fueled by oncology products, particularly ENHERTU, which retained leading market shares in the US, Europe ... Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results ...
Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...
Born in Alabama, educated in the U.S. and in Europe, Martin lives in Alabama ... and air,” says Kelly Johnson-Arbor, MD, a toxicologist at MedStar Health. “We currently do not know the toxic ...
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1.
AstraZeneca and Daiichii Sankyo’s antibody-drug conjugate (ADC ... teeing it up as the first ADC for cervical cancer to hit Europe pending final authorization. As for biosimilars, CHMP ...
(RTTNews) - Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive Officer, succeeding Sunao Manabe, with effect from ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
Europe as well as China, I visited all of their sites and I covered almost 90% of the employees in terms of market reach and explain with my own words the current state of Daiichi Sankyo and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback